Jazz Pharmaceuticals Reports $755 Million IPR&D Charge Following Actio Biosciences Acquisition
Jazz Pharmaceuticals (JAZZ) announced that its third-quarter financial results will be significantly impacted by a $755 million acquired in-process research and development (IPR&D) expense. This charge stems from the company's recent $1.32 billion acquisition of Actio Biosciences. The substantial one-time expense is expected to reduce both GAAP and non-GAAP adjusted earnings per share (EPS) for the third quarter. While the charge reflects the costs associated with integrating new research assets, it represents a significant immediate hit to the company's quarterly profitability metrics.
Tickers: $JAZZ
Topics: acquisition expense earnings impact EPS reduction in-process research and development
Read the full article at Seeking Alpha
Part of the story Jazz Pharmaceuticals Reports $755 Million IPR&D Charge Following Actio Biosciences Acquisition (3 articles)